- Home
- ATLN vs ALDX Comparison
ATLN vs ALDX Comparison
Compare ATLN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLN
- ALDX
- Stock Information
- Founded
- ATLN 2014
- ALDX 2004
- Country
- ATLN United States
- ALDX United States
- Employees
- ATLN N/A
- ALDX N/A
- Industry
- ATLN
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ATLN
- ALDX Health Care
- Exchange
- ATLN NYSE
- ALDX Nasdaq
- Market Cap
- ATLN 140.1M
- ALDX 160.8M
- IPO Year
- ATLN 2021
- ALDX 2014
- Fundamental
- Price
- ATLN $2.19
- ALDX $4.89
- Analyst Decision
- ATLN
- ALDX Strong Buy
- Analyst Count
- ATLN 0
- ALDX 2
- Target Price
- ATLN N/A
- ALDX $9.50
- AVG Volume (30 Days)
- ATLN 70.3K
- ALDX 1.2M
- Earning Date
- ATLN 08-22-2025
- ALDX 07-31-2025
- Dividend Yield
- ATLN N/A
- ALDX N/A
- EPS Growth
- ATLN N/A
- ALDX N/A
- EPS
- ATLN N/A
- ALDX N/A
- Revenue
- ATLN $444,795,409.00
- ALDX N/A
- Revenue This Year
- ATLN N/A
- ALDX N/A
- Revenue Next Year
- ATLN N/A
- ALDX N/A
- P/E Ratio
- ATLN N/A
- ALDX N/A
- Revenue Growth
- ATLN 10.11
- ALDX N/A
- 52 Week Low
- ATLN $1.68
- ALDX $1.14
- 52 Week High
- ATLN $7.97
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ATLN N/A
- ALDX 80.98
- Support Level
- ATLN N/A
- ALDX $4.12
- Resistance Level
- ATLN N/A
- ALDX $4.92
- Average True Range (ATR)
- ATLN 0.00
- ALDX 0.31
- MACD
- ATLN 0.00
- ALDX 0.09
- Stochastic Oscillator
- ATLN 0.00
- ALDX 94.44
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp is a U.S.-based outsourced services and workforce solutions company. The company specializes in permanent, temporary, and temporary-to-permanent placement services in various areas, including accounting and finance, administrative and clerical, hospitality, information technology, legal, light industrial, and medical fields. It also provides productivity consulting and workforce management solutions.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.